This trial studies how well contrast enhanced spectral mammography and magnetic resonance imaging work in detecting breast cancer. Diagnostic procedures, such as contrast enhanced spectral mammography and magnetic resonance imaging, may help find and diagnose breast cancer. Comparing results of diagnostic procedures done before biopsy may help doctors predict a patient's response to treatment and help plan the best treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03482557.
PRIMARY OBJECTIVE:
I. To determine whether contrast enhanced spectral mammography (CESM) is non-inferior to breast magnetic resonance imaging (MRI) for breast cancer screening.
SECONDARY OBJECTIVE:
I. To determine whether CESM is non-inferior to abbreviated breast MRI for breast cancer screening.
THIRD OBJECTIVE:
I. To determine whether CESM is superior to mammography for breast cancer screening.
FOURTH OBJECTIVE:
I. To determine patient preference for breast MRI versus CESM for breast cancer screening.
OUTLINE:
Prior to breast biopsy, participants undergo CESM and MRI within 3 months of each other.
After completion of study, participants are followed up for 2 years.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorOlga Rachel Brook